…or Economic Evaluation Alongside Controlled Trials if you don’t have to tweet it. Long overdue, but not a whole lot of changes in the grand scheme of things. Not very prescriptive at all, but a useful reference document. And…it comes with a recording of webinar that goes through the new document.
However, the context of EEACTs and their role needs to be fully appreciated. For this, can accompanying Editorial from Mark Sculper - Clinical Trials Provide Essential Evidence, but Rarely Offer a Vehicle for Cost-Effectiveness Analysis - is also recommended.